Abstract

This article addresses the treatment of VTE disease. We generated strong (Grade 1) and weak (Grade 2) recommendations based on high-quality (Grade A), moderate-quality (Grade B), and low-quality (Grade C) evidence. For acute DVT or pulmonary embolism (PE), we recommend initial parenteral anticoagulant therapy (Grade 1B) or anticoagulation with rivaroxaban. We suggest low-molecular-weight heparin (LMWH) or fondaparinux over IV unfractionated heparin (Grade 2C) or subcutaneous unfractionated heparin (Grade 2B). We suggest thrombolytic therapy for PE with hypotension (Grade 2C). For proximal DVT or PE, we recommend treatment of 3 months over shorter periods (Grade 1B). For a first proximal DVT or PE that is provoked by surgery or by a nonsurgical transient risk factor, we recommend 3 months of therapy (Grade 1B; Grade 2B if provoked by a nonsurgical risk factor and low or moderate bleeding risk); that is unprovoked, we suggest extended therapy if bleeding risk is low or moderate (Grade 2B) and recommend 3 months of therapy if bleeding risk is high (Grade 1B); and that is associated with active cancer, we recommend extended therapy (Grade 1B; Grade 2B if high bleeding risk) and suggest LMWH over vitamin K antagonists (Grade 2B). We suggest vitamin K antagonists or LMWH over dabigatran or rivaroxaban (Grade 2B). We suggest compression stockings to prevent the postthrombotic syndrome (Grade 2B). For extensive superficial vein thrombosis, we suggest prophylactic-dose fondaparinux or LMWH over no anticoagulation (Grade 2B), and suggest fondaparinux over LMWH (Grade 2C). Strong recommendations apply to most patients, whereas weak recommendations are sensitive to differences among patients, including their preferences.

Keywords

AntithromboticMedicineDiseaseIntensive care medicineInternal medicineCardiology

MeSH Terms

AdministrationOralAnticoagulantsDiagnostic ImagingDrug Administration ScheduleEvidence-Based MedicineFibrinolytic AgentsFondaparinuxHemorrhageHeparinLow-Molecular-WeightHumansInfusionsIntravenousInternational Normalized RatioLong-Term CarePolysaccharidesPulmonary EmbolismRisk FactorsSocietiesMedicalUnited StatesVenous ThrombosisVitamin K

Affiliated Institutions

Related Publications

Publication Info

Year
2012
Type
article
Volume
141
Issue
2
Pages
e419S-e496S
Citations
6084
Access
Closed

Social Impact

Altmetric

Social media, news, blog, policy document mentions

Citation Metrics

6084
OpenAlex
167
Influential
2865
CrossRef

Cite This

Clive Kearon, Elie A. Akl, Anthony J. Comerota et al. (2012). Antithrombotic Therapy for VTE Disease. CHEST Journal , 141 (2) , e419S-e496S. https://doi.org/10.1378/chest.11-2301

Identifiers

DOI
10.1378/chest.11-2301
PMID
22315268
PMCID
PMC3278049

Data Quality

Data completeness: 86%